These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1656474)

  • 21. Differential effects of mu-, delta- and kappa-opioid receptor agonists on the discriminative stimulus properties of cocaine in rats.
    Suzuki T; Mori T; Tsuji M; Maeda J; Kishimoto Y; Misawa M; Nagase H
    Eur J Pharmacol; 1997 Apr; 324(1):21-9. PubMed ID: 9137909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential antagonism of mu agonists by U50,488H in the rat.
    Porreca F; Tortella FC
    Life Sci; 1987 Dec; 41(23):2511-6. PubMed ID: 2824958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of U50,488H on locomotor activity in the hamster.
    Schnur P; Walker JM
    Pharmacol Biochem Behav; 1990 Aug; 36(4):813-6. PubMed ID: 2170998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.
    Pugsley MK; Penz WP; Walker MJ; Wong TM
    Br J Pharmacol; 1992 Mar; 105(3):521-6. PubMed ID: 1320979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-dimensional analyses of behavior in mice treated with U-50,488H, a purported kappa (non-mu) opioid agonist.
    Ukai M; Kameyama T
    Brain Res; 1985 Jul; 337(2):352-6. PubMed ID: 2992682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of a selective kappa-opioid agonist, U-50,488H, on morphine dependence in rats.
    Fukagawa Y; Katz JL; Suzuki T
    Eur J Pharmacol; 1989 Oct; 170(1-2):47-51. PubMed ID: 2558895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of T cell superantigen responses following treatment with the kappa-opioid agonist U50,488H.
    Guan L; Eisenstein TK; Adler MW; Rogers TJ
    J Neuroimmunol; 1997 May; 75(1-2):163-8. PubMed ID: 9143250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
    Wilson JL; Nayanar V; Walker JS
    Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord.
    Bhargava HN; Gulati A; Ramarao P
    J Pharmacol Exp Ther; 1989 Oct; 251(1):21-6. PubMed ID: 2552075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The kappa-opioid receptor agonist, U50,488H, exerts antidystonic activity in a mutant hamster model of generalized dystonia.
    Richter A; Löscher W
    Eur J Pharmacol; 1993 May; 236(2):289-94. PubMed ID: 8391460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of dynorphin A (1-13) and U50, 488H on free intracellular calcium in guinea pig cerebellar synaptosomes.
    Olson KG; Welch SP
    Life Sci; 1991; 48(6):575-81. PubMed ID: 1671526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of interleukin-1 and tumor necrosis factor-alpha synthesis following treatment of macrophages with the kappa opioid agonist U50, 488H.
    Belkowski SM; Alicea C; Eisenstein TK; Adler MW; Rogers TJ
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1491-6. PubMed ID: 7791124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitory effects of the kappa opiate U50,488 in the substantia nigra pars reticulata.
    Thompson LA; Walker JM
    Brain Res; 1990 May; 517(1-2):81-7. PubMed ID: 2165438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term voluntary access to running wheels decreases kappa-opioid antinociception.
    D'Anci KE; Gerstein AV; Kanarek RB
    Pharmacol Biochem Behav; 2000 Jun; 66(2):343-6. PubMed ID: 10880688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypes.
    Rothman RB; France CP; Bykov V; De Costa BR; Jacobson AE; Woods JH; Rice KC
    Eur J Pharmacol; 1989 Aug; 167(3):345-53. PubMed ID: 2553442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral kappa 1-opioid receptor-mediated analgesia in mice.
    Kolesnikov Y; Jain S; Wilson R; Pasternak GW
    Eur J Pharmacol; 1996 Aug; 310(2-3):141-3. PubMed ID: 8884210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological characterization of nalorphine, a kappa 3 analgesic.
    Paul D; Pick CG; Tive LA; Pasternak GW
    J Pharmacol Exp Ther; 1991 Apr; 257(1):1-7. PubMed ID: 1850462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down-regulation of central receptors for thyrotropin-releasing hormone in kappa opiate agonist-induced abstinence in the rat.
    Bhargava HN; Gulati A; Rahmani NH
    Neuropharmacology; 1992 Feb; 31(2):137-41. PubMed ID: 1313157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of U50,488, a selective kappa agonist, on atypical mouse opiate systems.
    Marrazzi MA; Lawhorn J; Graham V; L'Abbe D; Mullings-Britton J; Stack L; Eccles T
    Brain Res Bull; 1990 Jul; 25(1):199-201. PubMed ID: 2169965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of primary murine macrophage cytokine production in vitro following treatment with the kappa-opioid agonist U50,488H.
    Alicea C; Belkowski S; Eisenstein TK; Adler MW; Rogers TJ
    J Neuroimmunol; 1996 Jan; 64(1):83-90. PubMed ID: 8598393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.